Clinical Trial Search

Primary: AUClast: Area Under the Serum Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Vedolizumab SC — 492.6; 455.4 microgram*day per…

Primary: Change From Baseline in Palmar Sweat Production — 44.8; 43.2; 37.8; 24.9 mg/min

Primary: AMP Challenge Test PC20 — 79.21; 79.74; 62.69; 92.1 mg/ml

Primary: Early Postresuscitation Arterial Blood Pressure (mmHg) Measured Through Institution of Invasive Intra-arterial Pressure Monitoring (as Feasible). — 78.4; 75.1 mmHg…

Primary: Brown Adipose Tissue Activity — 3.9; 4.0 Standard uptake value (SUV) — p=0.84

Primary: IIEF (International Index of Erectile Function) Score - Screen — 34; 43; 57; 41 score on a scale

Primary: Number of Participants Who Experienced Adverse Events — 1; 7 participants

Primary: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) — 14; 6; 0; 0 Participants

Primary: Changes in Platelet Activation Marker Adenosin Diphosphate (%) — 63; 64.4; 64.4; 61.1 percentage of ADP

Primary: Functional Outcome 6 Months After Injury, as Measured by the Processing Speed Index — 82.5; 82.5 Processing speed index standardized scor

Primary: Percentage of Participants With Complications in the General Pacemaker Population — 3.33 percentage of subjects

Primary: Number of Participants With Entrance Block Confirmation in the Total Effectiveness Outcome Population — 46; 1 Participants

Primary: ETA Reading at Index Procedure vs. Actual Gaps at 1-month Restudy — 231; 1549; 48; 13 participants

Primary: Change in 24 Hour Diastolic Blood Pressure (DBP) — 3; 3 mmHg

Primary: Percent Change in Plasma Concentration of Inflammatory Biomarkers IL-6 (pg/mL) and PBMC TNF-α (pg/mL) — 1.92; -1.27; 7.19; 4.45 percentage of change in plasma levels…